» Articles » PMID: 37038432

Involvement of Transforming Growth Factor-β-Associated Kinase 1 in Fixed Airway Obstruction in Asthmatic Patients with Longer Disease Duration Independent on Airway Eosinophilia

Overview
Publisher Dove Medical Press
Date 2023 Apr 11
PMID 37038432
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Transforming growth factor-β-associated kinase 1 (TAK1) mediates non-canonical TGF-β signalling by promoting adhesive, migratory, proliferative and contractile responses of fibroblasts to TGF-β. However, TAK1 expression status in asthmatic patients with or without fixed airway obstruction (FAO) is unknown.

Patients And Methods: A total of 60 adult asthmatics with FAO were recruited and compared to 43 those without FAO (nFAO). TGF-β concentrations, and total TAK1 and phosphorylated TAK1 (p-TAK1) levels were determined in sputum supernatants, cytospin, and whole cell lysate by ELISA, immunocytochemistry, and Western blot analysis, respectively, in asthmatics with and without FAO.

Results: Asthmatic patients with FAO had much greater sputum TGF-β concentrations than those without FAO. This was independent of airway eosinophilia as there was no significant difference in TGF-β levels between high and low eosinophil counts within FAO and nFAO groups. In contrast, patients with FAO in the presence of sputum eosinophilia had greater expression of TAK1 and p-TAK1 than those without sputum eosinophilia (=0.0032 and =0.0061, respectively). The Western Blot data of total TAK1 and p-TAK1 were consistent with the immunocytochemistry, showing upregulation in all sputum cell types (neutrophils, eosinophils, macrophages, lymphocytes and airway epithelial cells). In addition, total TAK1 expression negatively correlated with pre- and post-bronchodilator FEV/FVC ratio.

Conclusion: TAK1 may play a key role in asthmatic patients with fixed airway obstruction, which was independent of eosinophilic airway inflammation. The interruption of TAK1 might have favourable clinical impact.

Citing Articles

N-cadherin antagonism is bronchoprotective in severe asthma models.

Pereira N, Schaible N, Desai A, Chan E, Ablooglu A, Capuano J Sci Adv. 2024; 10(48):eadp8872.

PMID: 39612338 PMC: 11606448. DOI: 10.1126/sciadv.adp8872.


CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy.

Mohammad Taheri M, Javan F, Poudineh M, Athari S Clin Rev Allergy Immunol. 2024; 66(3):328-362.

PMID: 38995478 DOI: 10.1007/s12016-024-08998-0.

References
1.
Crespo-Lessmann A, Curto E, Mateus Medina E, Palones E, Belda Soler A, Sanchez Maza S . Characteristics of Induced-Sputum Inflammatory Phenotypes in Adults with Asthma: Predictors of Bronchial Eosinophilia. J Asthma Allergy. 2023; 16:95-103. PMC: 9869783. DOI: 10.2147/JAA.S389402. View

2.
Mo Y, Kim Y, Bang J, Jung J, Lee C, Elias J . Mesenchymal Stem Cells Attenuate Asthmatic Inflammation and Airway Remodeling by Modulating Macrophages/Monocytes in the IL-13-Overexpressing Mouse Model. Immune Netw. 2022; 22(5):e40. PMC: 9634145. DOI: 10.4110/in.2022.22.e40. View

3.
. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis. 1987; 136(1):225-44. DOI: 10.1164/ajrccm/136.1.225. View

4.
Thompson K, Murphy-Marshman H, Leask A . ALK5 inhibition blocks TGFβ-induced CCN1 expression in human foreskin fibroblasts. J Cell Commun Signal. 2014; 8(1):59-63. PMC: 3972393. DOI: 10.1007/s12079-014-0229-7. View

5.
Ito K, Jazrawi E, Cosio B, Barnes P, Adcock I . p65-activated histone acetyltransferase activity is repressed by glucocorticoids: mifepristone fails to recruit HDAC2 to the p65-HAT complex. J Biol Chem. 2001; 276(32):30208-15. DOI: 10.1074/jbc.M103604200. View